Abstract
BackgroundThe recent use of targeted therapies and immunotherapy has considerably improved the survival of patients with Non-Small Cell Lung Cancer (NSCLC), in particular metastatic ones. In this new era, it...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
